AstraZeneca and Ionis Pharmaceuticals saw their shares drop after their jointly developed heart disease drug, Wainua, failed a late-stage trial. The drug, designed as a monthly gene silencer injection, did not show a statistically significant benefit in reducing cardiovascular-related deaths. This setback caused AstraZeneca's stock to fall about 8% in London, reflecting investor disappointment. The failure raises questions about the future of this treatment and impacts both companies' market valuations.
AstraZeneca announced that its drug Tezspire met all primary and key secondary goals in a late-stage trial for eosinophilic esophagitis, a chronic condition causing inflammation and difficulty swallowing. The trial involved 368 patients who received ...
AstraZeneca has priced a €2.55 billion bond issuance split into four fixed-rate tranches maturing between 2030 and 2038. The bonds, issued by its US subsidiary and guaranteed by the parent company, carry coupons ranging from 3.402% to 4.169%, reflect...
AstraZeneca faced a setback with the discontinuation of its volrustomig trial for non-small cell lung cancer, but strong clinical results for drugs like Tagrisso and Enhertu support its growth prospects. Investment firm CICC gave AstraZeneca an "Outp...
